CompletedNCT03455387
Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.
Studying HELLP syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier Metropole Savoie
- Principal Investigator
- Christophe DOCHECentre Hospitalier Metropole Savoie
- Intervention
- sampling of the serum marker sFlt1 and PlGF(diagnostic_test)
- Enrollment
- 233 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2017 – 2019
Study locations (7)
- CHMetropoleSavoie, Chambéry, Savoie, France
- CHU de Brest, Brest, France
- Centre Hospitalier Alpes Léman, Contamine-sur-Arve, France
- Groupe Hospitalier du Havre, Le Havre, France
- CHU de Limoges, Limoges, France
- Centre Hospitalier Annecy Genevois, Metz-Tessy, France
- Hôpitaux du Léman, Thonon-les-Bains, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03455387 on ClinicalTrials.govOther trials for HELLP syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07151339Pilot Project Renal and Cardiovascular Tertiary Prevention in PreeclampsiaUniversity Hospital Schleswig-Holstein
- RECRUITINGNCT05500989PlacEntal Acute Atherosis RefLecting Subclinical AtherosclerosisMaastricht University Medical Center
- RECRUITINGNCT06377878The Preeclampsia RegistryPreeclampsia Foundation